Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
35.89
-0.44 (-1.21%)
Nov 18, 2025, 4:00 PM EST - Market closed
Assembly Biosciences Revenue
Assembly Biosciences had revenue of $10.79M in the quarter ending September 30, 2025, with 57.62% growth. This brings the company's revenue in the last twelve months to $37.19M, up 31.30% year-over-year. In the year 2024, Assembly Biosciences had annual revenue of $28.52M with 298.16% growth.
Revenue (ttm)
$37.19M
Revenue Growth
+31.30%
P/S Ratio
8.31
Revenue / Employee
$509,466
Employees
73
Market Cap
567.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.52M | 21.36M | 298.16% |
| Dec 31, 2023 | 7.16M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 6.25M | -72.85M | -92.09% |
| Dec 31, 2020 | 79.11M | 63.14M | 395.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ASMB News
- 8 days ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 11 days ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire
- 5 weeks ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire
- 5 weeks ago - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe - GlobeNewsWire
- 7 weeks ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 3 months ago - Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts - Seeking Alpha
- 3 months ago - Assembly Biosciences Announces Pricing of $175 Million in Equity Financings - GlobeNewsWire
- 3 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire